SG11201606576UA - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors - Google Patents
Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitorsInfo
- Publication number
- SG11201606576UA SG11201606576UA SG11201606576UA SG11201606576UA SG11201606576UA SG 11201606576U A SG11201606576U A SG 11201606576UA SG 11201606576U A SG11201606576U A SG 11201606576UA SG 11201606576U A SG11201606576U A SG 11201606576UA SG 11201606576U A SG11201606576U A SG 11201606576UA
- Authority
- SG
- Singapore
- Prior art keywords
- phosphoinositide
- kinase inhibitors
- heterocyclic compounds
- tricyclic heterocyclic
- tricyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1402431.9A GB201402431D0 (en) | 2014-02-12 | 2014-02-12 | Compounds |
PCT/GB2015/050396 WO2015121657A1 (en) | 2014-02-12 | 2015-02-12 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201606576UA true SG11201606576UA (en) | 2016-09-29 |
Family
ID=50390862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201606576UA SG11201606576UA (en) | 2014-02-12 | 2015-02-12 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Country Status (27)
Country | Link |
---|---|
US (4) | US9981987B2 (en) |
EP (1) | EP3105233B1 (en) |
JP (1) | JP6516371B2 (en) |
KR (1) | KR102491796B1 (en) |
CN (1) | CN106103450B (en) |
AU (1) | AU2015216702B2 (en) |
BR (1) | BR112016019462B8 (en) |
CA (1) | CA2939045C (en) |
CY (1) | CY1120325T1 (en) |
DK (1) | DK3105233T3 (en) |
ES (1) | ES2673278T3 (en) |
GB (1) | GB201402431D0 (en) |
HR (1) | HRP20180768T1 (en) |
HU (1) | HUE037210T2 (en) |
IL (1) | IL247103B (en) |
LT (1) | LT3105233T (en) |
MX (1) | MX370151B (en) |
NO (1) | NO3105233T3 (en) |
NZ (1) | NZ723502A (en) |
PL (1) | PL3105233T3 (en) |
PT (1) | PT3105233T (en) |
RS (1) | RS57296B1 (en) |
SG (1) | SG11201606576UA (en) |
SI (1) | SI3105233T1 (en) |
TR (1) | TR201807906T4 (en) |
WO (1) | WO2015121657A1 (en) |
ZA (1) | ZA201605586B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2467387T3 (en) | 2009-08-20 | 2015-08-31 | Karus Therapeutics Ltd | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors. |
GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
NZ707366A (en) | 2012-11-07 | 2018-11-30 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors and their use in therapy |
DK2994465T3 (en) | 2013-05-10 | 2018-10-08 | Karus Therapeutics Ltd | HISTONDEACETYLASE INHIBITORS UNKNOWN |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
GB201514754D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
GB201514760D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514756D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
WO2021113633A1 (en) | 2019-12-05 | 2021-06-10 | Verge Analytics, Inc. | Fused tricyclic heterocyclic compounds as inhibitors of pikfyve kinase useful for the treatment of neurological diseases |
WO2022169882A1 (en) | 2021-02-03 | 2022-08-11 | Verge Analytics, Inc. | Methods and treatment of viral infection caused by sars-cov-2 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1445742A1 (en) | 1963-11-06 | 1968-12-19 | Bayer Ag | Process for the preparation of 2-position substituted benzoxazinones |
US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
BE786081A (en) | 1971-07-13 | 1973-01-10 | Uniroyal Sa | APPARATUS AND METHOD FOR MAINTAINING THE LINKAGES OF THE TIRE BOLTS |
US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
EP1200090B1 (en) | 1999-08-03 | 2013-09-11 | ICOS Corporation | Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction |
CN100345830C (en) | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | Condensed heteroaryl derivatives |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
WO2002002551A1 (en) | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
CA2491191C (en) | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
FR2846657B1 (en) | 2002-11-05 | 2004-12-24 | Servier Lab | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP1724267B1 (en) | 2004-02-26 | 2013-11-06 | ASKA Pharmaceutical Co., Ltd. | Pyrimidine derivative |
CA2567883A1 (en) | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
EP2354139A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
TW200738709A (en) | 2006-01-19 | 2007-10-16 | Osi Pharm Inc | Fused heterobicyclic kinase inhibitors |
AU2007242594A1 (en) | 2006-04-26 | 2007-11-01 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as PI3K inhibitors |
CN101511840A (en) | 2006-04-26 | 2009-08-19 | 吉宁特有限公司 | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
US8242116B2 (en) | 2006-06-26 | 2012-08-14 | Ucb Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
CN101605797A (en) | 2006-11-13 | 2009-12-16 | 伊莱利利公司 | The Thienopyrimidinones of treatment inflammatory disease and cancer |
AU2007334343A1 (en) | 2006-12-15 | 2008-06-26 | Ordway Research Institute, Inc. | Treatments of therapy-resistant diseases comprising drug combinations |
JP2010518014A (en) | 2007-01-31 | 2010-05-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 2-Aminopyridine derivatives useful as kinase inhibitors |
WO2008121257A1 (en) | 2007-03-28 | 2008-10-09 | Merck & Co., Inc. | Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators |
JP2010529031A (en) | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Naphthyridine derivatives as PI3 kinase inhibitors |
GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
EP2158207B1 (en) * | 2007-06-12 | 2011-05-25 | F. Hoffmann-La Roche AG | Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
WO2008152394A1 (en) * | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
WO2010015520A1 (en) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and use thereof as medicines |
AU2009299894A1 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4 -morpholino-pyrido [3, 2 -d] pyrimidines active on Pi3k |
GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
WO2011012883A1 (en) | 2009-07-29 | 2011-02-03 | Karus Therapeutics Limited | Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
PL2467387T3 (en) | 2009-08-20 | 2015-08-31 | Karus Therapeutics Ltd | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors. |
WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EP4086246A1 (en) | 2011-07-27 | 2022-11-09 | AstraZeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds as egfr modulators |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
WO2014081718A1 (en) | 2012-11-20 | 2014-05-30 | Genentech, Inc. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
DK2994465T3 (en) | 2013-05-10 | 2018-10-08 | Karus Therapeutics Ltd | HISTONDEACETYLASE INHIBITORS UNKNOWN |
BR112015029969A2 (en) | 2013-05-30 | 2017-07-25 | Infinity Pharmaceuticals Inc | cancer treatment using pi3 isoform kinase modulators |
EP3052494B1 (en) | 2013-06-28 | 2018-12-26 | H. Hoffnabb-La Roche Ag | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
US9403779B2 (en) | 2013-10-08 | 2016-08-02 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors |
JP6584391B2 (en) | 2013-10-10 | 2019-10-02 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | HDAC inhibitors alone or in combination with PI3K inhibitors to treat non-Hodgkin lymphoma |
GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
MA40933A (en) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
-
2014
- 2014-02-12 GB GBGB1402431.9A patent/GB201402431D0/en not_active Ceased
-
2015
- 2015-02-12 MX MX2016010404A patent/MX370151B/en active IP Right Grant
- 2015-02-12 CA CA2939045A patent/CA2939045C/en active Active
- 2015-02-12 ES ES15707168.9T patent/ES2673278T3/en active Active
- 2015-02-12 AU AU2015216702A patent/AU2015216702B2/en active Active
- 2015-02-12 US US15/117,606 patent/US9981987B2/en active Active
- 2015-02-12 DK DK15707168.9T patent/DK3105233T3/en active
- 2015-02-12 LT LTEP15707168.9T patent/LT3105233T/en unknown
- 2015-02-12 SG SG11201606576UA patent/SG11201606576UA/en unknown
- 2015-02-12 CN CN201580008209.5A patent/CN106103450B/en active Active
- 2015-02-12 NZ NZ723502A patent/NZ723502A/en unknown
- 2015-02-12 SI SI201530269T patent/SI3105233T1/en unknown
- 2015-02-12 TR TR2018/07906T patent/TR201807906T4/en unknown
- 2015-02-12 PL PL15707168T patent/PL3105233T3/en unknown
- 2015-02-12 BR BR112016019462A patent/BR112016019462B8/en active IP Right Grant
- 2015-02-12 KR KR1020167025096A patent/KR102491796B1/en active IP Right Grant
- 2015-02-12 JP JP2016568145A patent/JP6516371B2/en active Active
- 2015-02-12 PT PT157071689T patent/PT3105233T/en unknown
- 2015-02-12 WO PCT/GB2015/050396 patent/WO2015121657A1/en active Application Filing
- 2015-02-12 NO NO15707168A patent/NO3105233T3/no unknown
- 2015-02-12 RS RS20180614A patent/RS57296B1/en unknown
- 2015-02-12 EP EP15707168.9A patent/EP3105233B1/en active Active
- 2015-02-12 HU HUE15707168A patent/HUE037210T2/en unknown
-
2016
- 2016-08-04 IL IL247103A patent/IL247103B/en active IP Right Grant
- 2016-08-12 ZA ZA201605586A patent/ZA201605586B/en unknown
-
2018
- 2018-04-24 US US15/961,404 patent/US10513530B2/en active Active
- 2018-05-16 HR HRP20180768TT patent/HRP20180768T1/en unknown
- 2018-06-11 CY CY20181100607T patent/CY1120325T1/en unknown
-
2019
- 2019-11-08 US US16/678,565 patent/US20200354378A1/en not_active Abandoned
-
2021
- 2021-03-19 US US17/206,488 patent/US11708378B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284952A (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
ZA201605586B (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
HK1231411A1 (en) | Substituted indazole compounds as irak4 inhibitors irak4 | |
HK1231480A1 (en) | Indazole compounds as irak4 inhibitors irak4 | |
HK1223100A1 (en) | Heterocyclic compounds | |
HUE059324T2 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
IL251932A0 (en) | Benzylpropargylether as nitrification inhibitors | |
IL251780A0 (en) | New compounds as nik inhibitors | |
IL251778B (en) | New pyrazolopyrimidine derivatives as nik inhibitors | |
GB201403536D0 (en) | Inhibitor compounds | |
IL254424A0 (en) | Substituted tricyclic heterocyclic compounds | |
SI3159335T1 (en) | Novel heterocyclic compound | |
PL3191491T3 (en) | Pyridazinone derivatives as phosphoinositide 3-kinases inhibitors |